10x Genomics, Inc. (TXG) FY2026 YTD Q2 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2026-01-01 to 2026-06-30

Swipe to see the full flow
10x Genomics, Inc. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Orange marks positive customer-advance and deferred-revenue changes that add to operating cash in the reconciliation. These are net changes, not gross customer receipts. Negative changes are neutral reconciliation adjustments; they do not by themselves identify cash payments. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Stock-based compensation expense → operating reconciliation: $48,258,000.00Other receivables → operating reconciliation: $32,147,000.00Depreciation and amortization → operating reconciliation: $19,621,000.00Accounts payable → operating reconciliation: $8,072,000.00Inventory → operating reconciliation: $5,703,000.00Non-cash lease expense → operating reconciliation: $3,969,000.00Fair value adjustments on contingent consideration → operating reconciliation: $3,466,000.00Prepaid expenses and other current assets → operating reconciliation: $3,151,000.00Other noncurrent liabilities → operating reconciliation: $90,000.00operating reconciliation → Net cash from operating activities: $43,094,000.00operating reconciliation → Net income (loss): $31,401,000.00operating reconciliation → Accrued compensation and other related benefits: $17,833,000.00operating reconciliation → Other noncurrent assets: $11,923,000.00operating reconciliation → Accrued expenses and other current liabilities: $9,694,000.00operating reconciliation → Operating lease liability: $5,826,000.00operating reconciliation → Deferred revenue: $1,509,000.00operating reconciliation → Deferred income taxes: $1,434,000.00operating reconciliation → Other: $616,000.00operating reconciliation → Accrued contingent consideration and assumed liabilities: $613,000.00operating reconciliation → Accounts receivable: $534,000.00Proceeds from maturities of marketable securities → investing reconciliation: $50,000,000.00investing reconciliation → Purchases of marketable securities: $49,260,000.00investing reconciliation → Business combination: $6,101,000.00investing reconciliation → Purchases of property and equipment: $3,185,000.00investing reconciliation → Purchase of equity interest rights: $500,000.00Net cash used in financing activities → financing reconciliation: $5,401,000.00Issuance of common stock from exercise of stock options → financing reconciliation: $3,289,000.00financing reconciliation → Payment of contingent consideration: $8,690,000.00Net cash used in investing activities → investing reconciliation: $9,046,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $473,966,000.00Net cash from operating activities → Cash sources and uses: $43,094,000.00Cash sources and uses → Exchange-rate effect: $101,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $502,512,000.00Cash sources and uses → Net cash used in investing activities: $9,046,000.00Cash sources and uses → Net cash used in financing activities: $5,401,000.00Net income (loss): -$31,401,000.00Net income (loss)−$31.40 MStock-based compensation expense: $48,258,000.00Stock-based compensation+$48.26 MDepreciation and amortization: $19,621,000.00Depreciation & amortization+$19.62 MNon-cash lease expense: $3,969,000.00Operating lease amortization+$3.97 MFair value adjustments on contingent consideration: $3,466,000.00Contingent consideration fair value+$3.47 MAsset and lease impairment charges: $0.00Deferred income taxes: -$1,434,000.00Deferred income taxes−$1.43 MOther: -$616,000.00Other operating, net−$616.00 KAccounts receivable: -$534,000.00Accounts receivable−$534.00 KOther receivables: $32,147,000.00Other receivables+$32.15 MInventory: $5,703,000.00Inventories+$5.70 MPrepaid expenses and other current assets: $3,151,000.00Prepaid & other assets+$3.15 MOther noncurrent assets: -$11,923,000.00Other operating assets−$11.92 MAccounts payable: $8,072,000.00Accounts payable+$8.07 MAccrued compensation and other related benefits: -$17,833,000.00Accrued compensation−$17.83 MDeferred revenue: -$1,509,000.00Unearned revenue−$1.51 MAccrued contingent consideration and assumed liabilities: -$613,000.00Accrued contingent consideration−$613.00 KAccrued expenses and other current liabilities: -$9,694,000.00Accrued & other liabilities−$9.69 MOperating lease liability: -$5,826,000.00Operating lease liabilities−$5.83 MOther noncurrent liabilities: $90,000.00Other noncurrent liabilities+$90.00 KNet cash from operating activities: $43,094,000.00Operating cash+$43.09 Moperating reconciliation: $124,477,000.00Payment of contingent consideration: -$8,690,000.00Contingent consideration paid−$8.69 MIssuance of common stock from exercise of stock options: $3,289,000.00Employee stock plans & options+$3.29 MNet cash used in financing activities: -$5,401,000.00. Cash required to fund net payments.Financing cash−$5.40 Mfinancing reconciliation: $8,690,000.00Business combination: -$6,101,000.00Acquisitions, net of cash−$6.10 MPurchases of property and equipment: -$3,185,000.00PP&E purchases−$3.19 MPurchases of marketable securities: -$49,260,000.00AFS securities purchases−$49.26 MProceeds from maturities of marketable securities: $50,000,000.00AFS securities maturities+$50.00 MPurchase of equity interest rights: -$500,000.00Equity interest rights purchases−$500.00 KNet cash used in investing activities: -$9,046,000.00. Cash required to fund net payments.Investing cash−$9.05 Minvesting reconciliation: $59,046,000.00Cash sources and uses: $517,060,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $473,966,000.00Beginning cash$473.97 MEnding cash: Cash, cash equivalents, and restricted cash: $502,512,000.00Ending cash$502.51 MExchange-rate effect: -$101,000.00FX effect−$101.00 KCASH RECONCILIATIONOperatingflowsInvestingflowsFinancingflowsNet loss −$31.40M + net operating adjustments $74.50M = operating cash +$43.09MFree cash flow$39.91 MOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change+$28.55 MEnding cash − beginning cash
Chart details

10x Genomics, Inc. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026

Cash flows for Jan 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
473,966,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
43,094,000 US dollars. Net cash provided.
Net income (loss)
negative 31,401,000 US dollars
Stock-based compensation expense
48,258,000 US dollars
Depreciation and amortization
19,621,000 US dollars
Non-cash lease expense
3,969,000 US dollars
Fair value adjustments on contingent consideration
3,466,000 US dollars
Asset and lease impairment charges
0 US dollars
Deferred income taxes
negative 1,434,000 US dollars
Other
negative 616,000 US dollars
Accounts receivable
negative 534,000 US dollars
Other receivables
32,147,000 US dollars
Inventory
5,703,000 US dollars
Prepaid expenses and other current assets
3,151,000 US dollars
Other noncurrent assets
negative 11,923,000 US dollars
Accounts payable
8,072,000 US dollars
Accrued compensation and other related benefits
negative 17,833,000 US dollars
Deferred revenue
negative 1,509,000 US dollars
Accrued contingent consideration and assumed liabilities
negative 613,000 US dollars
Accrued expenses and other current liabilities
negative 9,694,000 US dollars
Operating lease liability
negative 5,826,000 US dollars
Other noncurrent liabilities
90,000 US dollars
Investing activities
negative 9,046,000 US dollars. Net cash used.
Business combination
negative 6,101,000 US dollars
Purchases of property and equipment
negative 3,185,000 US dollars
Purchases of marketable securities
negative 49,260,000 US dollars
Proceeds from maturities of marketable securities
50,000,000 US dollars
Purchase of equity interest rights
negative 500,000 US dollars
Financing activities
negative 5,401,000 US dollars. Net cash used.
Payment of contingent consideration
negative 8,690,000 US dollars
Issuance of common stock from exercise of stock options
3,289,000 US dollars
Operating adjustment reconciliation
124,477,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
8,690,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
59,046,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
negative 101,000 US dollars
Ending cash on Jun 30, 2026
502,512,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
517,060,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
28,546,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
43,094,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
3,185,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
39,909,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$31.40M + net operating adjustments $74.50M = operating cash +$43.09M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 43,094,000 US dollars minus 3,185,000 US dollars equals 39,909,000 US dollars.
10x Genomics, Inc. (TXG) FY2026 YTD Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!